Choline in acute coronary syndrome: an emerging biomarker with implications for the integrated assessment of plaque...

Area of Science:

• Biochemistry
• Cardiology
• Biomarker Discovery

Background:

• Choline metabolites are emerging as critical biomarkers in acute coronary syndrome (ACS).
• Coronary plaque instability, platelet thrombus formation, and ischemia are key pathological features of ACS.
• Existing biomarkers like troponins and inflammatory markers have limitations in early risk stratification.

Purpose of the Study:

• To review the role of choline in acute coronary syndrome (ACS).
• To explore choline's potential as an early predictor of cardiac events and its utility in risk stratification.
• To discuss integrated strategies for assessing plaque vulnerability using in vitro and in vivo choline measurements.

Main Methods:

• Review of existing literature on choline in ACS.
• Analysis of clinical studies investigating whole-blood, plasma, and serum choline levels.
• Discussion of analytical methods for choline measurement and in vivo imaging techniques.

Main Results:

• Whole-blood choline serves as an early predictor for cardiac events, augmenting current markers.
• Serum choline demonstrates high predictive value for myocardial infarction and risk subgroup discrimination in troponin-positive patients.
• Choline aids in differentiating ischemic from nonischemic etiologies of troponin elevations.

Conclusions:

• Choline is a valuable candidate biomarker for emergency room decision-making, especially with advanced troponin assays.
• Integrated in vitro and in vivo choline assessment offers a novel strategy for detecting vulnerable plaques.
• Choline measurement holds significant implications for the comprehensive assessment of plaque vulnerability in ACS.